Prevalence of SARS-CoV-2 antibodies at the University hospital Heidelberg and correlation with SARS-CoV-2 incidence

BACKGROUND: Since the onset of the SARS-CoV-2 pandemic in late 2019, many studies suggest that actual infection rates may far exceed reported cases. Therefore, this study provides a comprehensive overview of anti-SARS-CoV-2 antibody measurements and their significance in epidemiological surveillance, especially regarding the true extent of SARS-CoV-2 infections, allowing more detailed insights into the dynamics of the pandemic. METHODS: Antibodies were measured using the Elecsys® Anti-SARS-CoV-2 assay for the nucleocapsid (N) protein and the SARS-CoV-2 IgG (sCOVG) assay for the spike (S) protein. A total of 25197 specimens from University Hospital Heidelberg were analyzed between May 2020 and December 2023, with 16957 samples measured for both antibodies, 2756 for anti-N only, and 5484 for anti-S only. For the epidemiological tracing of the SARS-CoV-2 incidence we analyzed changes in the anti-N positivity rate and anti-S positivity rate within our tertiary hospital setting across consecutive quarters. RESULTS: Anti-N measurements allowed for a retrospective analysis of SARS-CoV-2 epidemiological developments, revealing significant changes (p <0.05) in the anti-N positivity rate following incidence peaks (increase) and low incidence periods (decrease) with only three non-significant transitions.On the other hand, the anti-S positivity rate showed only four significant transitions between consecutive quarters. CONCLUSION: The anti-N positivity rate is an effective and straightforward retrospective serological tool for tracking epidemiological trends, while the anti-S rate is influenced by vaccination and epidemiology as well, making it inept for the tracing of epidemiological changes. Although the recent development in SARS-CoV-2 epidemiology with increasing intervals between infection waves already provide an enhanced statistical robustness, we recommend the determination of the anti-N positivity rate in larger study populations.

Authors

Institutions

Publication Details

Journal
Heliyon
Published
2024-11-01
DOI
https://doi.org/10.1016/j.heliyon.2024.e40282
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prevalence of SARS-CoV-2 antibodies at the University hospital Heidelberg and correlation with SARS-CoV-2 incidence

Norbert Weidner, Christian Bundschuh, Timo Florian Martin Scholz, Hans‐Georg Kräusslich et al.
Heliyon
SARS-CoV-2 and COVID-19 Research
article

Prevalence of SARS-CoV-2 antibodies at the University hospital Heidelberg and correlation with SARS-CoV-2 incidence

Norbert Weidner, Christian Bundschuh, Timo Florian Martin Scholz, Hans‐Georg Kräusslich, Jost Langhorst, Sylvia Parthé, Edith Gößnitzer
article en

Abstract

BACKGROUND: Since the onset of the SARS-CoV-2 pandemic in late 2019, many studies suggest that actual infection rates may far exceed reported cases. Therefore, this study provides a comprehensive overview of anti-SARS-CoV-2 antibody measurements and their significance in epidemiological surveillance, especially regarding the true extent of SARS-CoV-2 infections, allowing more detailed insights into the dynamics of the pandemic. METHODS: Antibodies were measured using the Elecsys® Anti-SARS-CoV-2 assay for the nucleocapsid (N) protein and the SARS-CoV-2 IgG (sCOVG) assay for the spike (S) protein. A total of 25197 specimens from University Hospital Heidelberg were analyzed between May 2020 and December 2023, with 16957 samples measured for both antibodies, 2756 for anti-N only, and 5484 for anti-S only. For the epidemiological tracing of the SARS-CoV-2 incidence we analyzed changes in the anti-N positivity rate and anti-S positivity rate within our tertiary hospital setting across consecutive quarters. RESULTS: Anti-N measurements allowed for a retrospective analysis of SARS-CoV-2 epidemiological developments, revealing significant changes (p <0.05) in the anti-N positivity rate following incidence peaks (increase) and low incidence periods (decrease) with only three non-significant transitions.On the other hand, the anti-S positivity rate showed only four significant transitions between consecutive quarters. CONCLUSION: The anti-N positivity rate is an effective and straightforward retrospective serological tool for tracking epidemiological trends, while the anti-S rate is influenced by vaccination and epidemiology as well, making it inept for the tracing of epidemiological changes. Although the recent development in SARS-CoV-2 epidemiology with increasing intervals between infection waves already provide an enhanced statistical robustness, we recommend the determination of the anti-N positivity rate in larger study populations.

HeliyonVol. 10(22)
University of Graz (AT), Heidelberg University (DE), German Center for Infection Research (DE), Research Center Pharmaceutical Engineering (Austria) (AT)
Good health and well-being
Openalex Percentile: Top 74%
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.